Helmut Baranyovszki

Novartis Austria GmbH operates as a holding company, which engages in the development and production of pharmaceutical products. The company was founded on January 30, 2006 and is headquartered in Vienna, Austria.

aws-mittelstandsfonds Management GmbH provides investment services. It offers services that allows to increase production and marketing capacity and invest in new technologies. The company is headquartered in Vienna, Austria.

Austria Wirtschaftsservice GmbH (AWS) is the Austrian promotional bank, fully controlled by the Government of Austria. Based in Vienna, AWS emerged in 2002 from the merger of several government funding agencies including FGG-Finanzierungsgarantiegesellschaft mbH and BÜRGES Förderungsbank GmbH. The firm later absorbed Innovationsagentur GmbH. The Seed Financing division of AWS manages venture capital investments by way of mezzanine financing. AWS also comprises several divisions not directly involved in investment management, namely Tecma which is specialized in technology marketing support, Tecnet which supplies technology information, i²-Ideas & Investment which is a networking platform for business angels and Biotech, providing business support for biotechnology projects. AWS manages the university spin-off fund Uni Venture, sponsored by BAWAG-Bank für Arbeit und Wirtschaft.

AUSTRIANOVA Biomanufacturing AG engages in the developmente of proprietary drug delivery technologies in orphan niche indications in oncology. It offers NovaCaps, which targets tumours in pancreatic cancer. The company was founded in 2001 and is headquartered in Vienna, Austria.

Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland.

TTTech Computertechnik AG engages in the provision of aerospace, space, manufacturing and energy market solutions. The company was founded by Stefan Poledna and Gerog Kopetz in 1998 and is headquartered in Vienna, Austria.

WEB Windenergie AG provides renewable energy power. It offers wind energy, photovoltaic and hydroelectric power plants. The Company was founded by Erna Dangl, Frnaz Dangl and Andreas Dangl in 1994 and is headquartered in Pfaffenschlag, Austria.

Österreichische Bundesbahnen-Holding AG engages in the holding and management of participations in companies of the ÖBB Group with focus on strategic orientation. It also provides infrastructure, transportation, and logistics services. The company was founded on April 20, 2004 and is headquartered in Vienna, Austria.

Rail Cargo Austria AG engages in freight transport and logistics services. It specializes in wagonload and logistics, intermodal logistics, rolling road, railway undertaking, wagon rental and sales, as well as technical services and maintenance. The company was founded in 1992 and is headquartered in Vienna, Austria.

ÖBB-Personenverkehr AG provides passenger rail transportation. It operates suburban trains, long-distance trains, passenger wagons, railcars, and buses. The company was founded in 2004 and is headquartered in Vienna, Austria.

Infineon Technologies Austria AG engages in the development, production and sales of switching elements in microelectronics. The company was founded on March 24, 1999 and is headquartered in Villach, Austria.

aws Mittelstandsfonds Beteiligungs GmbH & Co KG is a private equity fund that invests in Austrian middle market companies with revenues at least EUR 2 million. It makes growth investments ranging to EUR 5 million, finances MBOs and MBIs, also invests in a form of silent partnerships. It makes minority investments. The fund has no sectorial preferences. Its usual investment period is up to 10 years.

Erdöl-Lagergesellschaft mbH engages in the provision of crude oil storage services. It is responsible for maintaining energy supply security during emergencies. The firm also imports petroleum products to other European countries. The company was founded in 1976 and is headquartered in Lannach, Austria.

AFFiRiS AG develops and produces vaccines for therapeutic treatment of chronic diseases. It provides research services and develops vaccines based on peptide antigens applied in the fields of biochemistry, molecular and cell biology, immunology and veterinary medicine. AFFiRiS was founded by Walter Schmidt and Frank Mattner in November 2003 and is headquartered in Vienna, Austria.

Aleph Zero Foundation is a Swiss company that provides an enterprise-ready, peer-reviewed blockchain solution. The company is based in Zug, Switzerland. The company's blockchain is scalable, fast, and developer-friendly. The company was founded by Michal Swietek, Adam Gagol, Antoni Zolciak, Matthew Niemerg.

Goetzpartners Securities Ltd. is the Great Britain-based brokerage subsidiary of goetzpartners Corporate Finance GmbH, which is owned by goetzpartners Holding GmbH & Co. KG in Germany. Headquartered in London, the firm was founded in 2003 to serve as a corporate broker for European healthcare companies. Goetzpartners Securities offers their corporate clients direct and well-established institutional buy-side access. They also provide access to high-net-worth individuals who are investing in healthcare sectors. Their equity sales team has broad geographic coverage, and offers specialist insight into healthcare capital markets.

Part of LTS LOHMANN Therapie-Systeme AG, CRS Clinical Research Services Andernach GmbH engages in research and development in natural sciences, engineering, agricultural sciences and medicine. The company is based in Andernach, Germany. The CEO of the German company is Torben Thomsen.

GBA Gesellschaft für Bioanalytik mbH engages in provision of analytical laboratory and consulting services. The firm’s services include environmental analysis, food analysis, GBA pharma and commodities analysis. The company was founded by Erich Döllefeld on June 27, 1989 and is headquartered in Hamburg, Germany.

ABF Pharmaceutical Services GmbH provides pharmaceutical services. The firm’s services include Clinical Trial Supply Services, Labeling and packaging, Storage, Import and Export, QP release, quality management, central lab supply services, PBMC and sourcing. The company was founded in 2004 and is headquartered in Vienna, Austria.

Boehringer Ingelheim RCV GmbH & Co. KG develops and supplies biotherapeutic proteins, plasmid DNA and antibody fragments. The company was founded in 1885 by Albert Boehringer and is headquartered in Vienna, Austria.

Quadia SA (Quadia) is an independent investment firm founded in 2010. The firm is headquartered in Switzerland.

Aravis Venture II LP invests in biotechnological start-ups with growth potential.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

DyCare is a Spanish company that specializes in digital rehabilitation. The company is based in Barcelona, Spain. The company creates ultra-personalized exercises and monitor patients in a simple and effective way. The company's technology allows patients to perform therapeutic exercises using only their mobile phone or tablet camera, assisted by artificial intelligence. The company was founded by Silvia Raga and Ricardo Jauregui, who have been the CEOs since incorporation.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.